Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism - Yang, S H; Xu, R X; Cui, C J (Cardiovasc Diabetol, 2018)
et al.